CONSUN PHARMAC.GR.HD -10 (F:C1P) — Stock Price
CONSUN PHARMAC.GR.HD -10 (F:C1P) is currently trading at €1.50 EUR, up 0.00% today. Over the past 52 weeks, shares have ranged between €1.30 and €2.18. This page tracks CONSUN PHARMAC.GR.HD -10's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of CONSUN PHARMAC.GR.HD -10.
CONSUN PHARMAC.GR.HD -10 (C1P) Stock Price Chart — Daily History & Trading Volume
The chart below tracks CONSUN PHARMAC.GR.HD -10's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
CONSUN PHARMAC.GR.HD -10 Income Statement — Revenue, Profit & Earnings by Year
CONSUN PHARMAC.GR.HD -10's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €3.42 Billion | €2.97 Billion | €2.59 Billion | €2.34 Billion | €2.04 Billion |
| Cost of Revenue | €750.24 Million | €725.13 Million | €668.44 Million | €576.74 Million | €517.32 Million |
| Gross Profit | €2.67 Billion | €2.24 Billion | €1.92 Billion | €1.76 Billion | €1.53 Billion |
| Research & Development | — | — | — | — | — |
| SG&A | €1.52 Billion | €1.29 Billion | €1.17 Billion | €1.09 Billion | €900.00 Million |
| Total Operating Expenses | €2.26 Billion | €2.00 Billion | €1.78 Billion | €1.62 Billion | €1.39 Billion |
| Operating Income | €1.15 Billion | €962.77 Million | €810.03 Million | €719.46 Million | €652.31 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €4.36 Million | €24.89 Million | €21.26 Million | €10.93 Million | €12.90 Million |
| Income Before Tax | €1.20 Billion | €1.02 Billion | €863.70 Million | €746.39 Million | €695.86 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €1.08 Billion | €910.46 Million | €784.53 Million | €682.91 Million | €590.17 Million |
CONSUN PHARMAC.GR.HD -10 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes CONSUN PHARMAC.GR.HD -10's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €6.41 Billion | €5.85 Billion | €5.51 Billion | €4.89 Billion | €4.36 Billion |
| Total Current Assets | €4.60 Billion | €4.55 Billion | €4.28 Billion | €3.62 Billion | €3.06 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €2.67 Billion | €958.00 Million | €834.94 Million | €589.17 Million | €230.00 Million |
| Net Receivables | €251.32 Million | €234.19 Million | €195.07 Million | €163.24 Million | €222.59 Million |
| Inventory | €271.40 Million | €289.68 Million | €367.09 Million | €276.08 Million | €243.03 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €1.57 Billion | €1.46 Billion | €1.59 Billion | €1.45 Billion | €1.45 Billion |
| Total Current Liabilities | €1.43 Billion | €1.37 Billion | €1.49 Billion | €1.35 Billion | €1.36 Billion |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €4.54 Billion | €4.10 Billion | €3.63 Billion | €3.15 Billion | €2.62 Billion |
| Retained Earnings | €3.99 Billion | €3.41 Billion | €3.14 Billion | €2.68 Billion | €2.16 Billion |
CONSUN PHARMAC.GR.HD -10 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how CONSUN PHARMAC.GR.HD -10 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €1.21 Billion | €1.09 Billion | €818.97 Million | €947.68 Million | €725.54 Million |
| Capital Expenditures | €68.48 Million | €109.00 Million | €52.56 Million | €51.59 Million | €98.25 Million |
| Free Cash Flow | €1.14 Billion | €977.99 Million | €766.41 Million | €896.09 Million | €627.29 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | €-498.39 Million | €-680.54 Million | €326.25 Million | €127.49 Million | €198.08 Million |
| Stock-Based Compensation | — | — | €0.00 | €-1.78 Million | €23.41 Million |
| Depreciation | €66.59 Million | €63.99 Million | €78.09 Million | €76.36 Million | €72.99 Million |
| Change in Cash | €-1.65 Billion | €170.82 Million | €307.10 Million | €236.67 Million | €260.57 Million |
CONSUN PHARMAC.GR.HD -10 Earnings History — EPS Actual vs. Analyst Estimates
Track CONSUN PHARMAC.GR.HD -10's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 26, 2025 | — | — | — |